-
Efforts to decrease door-to-balloon time for primary percutaneous intervention (PCI) in an acute ST elevation myocardial infarction (STEMI), may include preferential triage to hospitals expert in primary PCI, partly because of evidence suggesting better outcomes.
-
Revascularization, in conjunction with optimal medical therapy, remains a critical component in therapy for patients with obstructive coronary artery disease (CAD).
-
Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.
-
Genetic research and results are playing an increasingly large role in clinical medicine. I suspect that most physicians are not adequately knowledgeable about genetics; nor am I. At present, the genetics of clopidogrel and warfarin are front and center, as well as an increasing number of genetic studies dealing with normal metabolism, as well as dyslipidemia.
-
Nebivolol is a new beta 1 selective blocker with vasodilatation properties via activation of the L-arginine/nitric oxide pathway. Short-term studies, and a long-term, open-label study, have shown excellent efficacy and safety in stages 1-11 hypertension.
-
Ray et al examined the computerized files of Tennessee Medicaid recipients to estimate the effects of atypical antipsychotic drugs on the risk of sudden cardiac death.
-
The goal of treatment during ST elevation myocardial infarction (STEMI) is early reperfusion of the occluded coronary artery, as this has been shown to reduce mortality and morbidity.
-
FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
-
In this paper, stevenson et al, from 18 centers with expertise in ventricular tachycardia (VT) ablation, report the results of VT ablation using the Thermo°Cool-irrigated, tipped-radiofrequency ablation catheter. Patients were eligible for the study if they had multiple episodes of sustained monomorphic VT that had required either cardioversion or antiarrhythmic drug administration in the previous six months.
